SWAAT: a simple mnemonic to promote lifestyle change for blood pressure control

The nature of individuals living with elevated blood pressure has changed significantly in recent decades. Whereas previously hypertension was often associated with ageing and genetic predisposition, today it is increasingly driven by excess body weight and the broader obesogenic environment [1]. This environment promotes overconsumption of calories and salt while simultaneously encouraging sedentary behaviours. These factors collectively contribute to rising blood pressure levels across populations. Other factors can include hypertensive disorders of pregnancy (preeclampsia, gestational hypertension) [2,3], and juvenile hypertension, though these are all also likely to be more often obesity driven. Blood pressure remains a critical, modifiable risk factor for future adverse cardiovascular and metabolic outcomes [4]. Blood pressure measurement is non-invasive, widely available, provides a quantitative assessment, and serves as a direct surrogate marker for cardiovascular outcomes, which can serve as a practical biomarker of health improvement. The evidence base is clear: weight reduction, increased physical activity, reduced salt intake, and lower alcohol consumption all contribute meaningfully to lowering blood pressure [5–7]. Specifically, for alcohol, there is a well-documented linear relationship between intake and systolic blood pressure [8]. Despite this knowledge, translating these principles into actionable steps for patients remains challenging. Healthcare professionals and patients alike need simple, memorable tools to guide lifestyle modification before pharmacological intervention becomes necessary. To address this gap, we propose a new mnemonic: SWAAT, which stands for: 1. Salt – Reduce added salt and limit high-salt foods and consider potassium-rich alternatives. 2. Weight – Aim for meaningful, sustainable weight loss through a balanced diet and activity. 3. Alcohol – Cut alcohol intake; consider low-calorie alternatives to reduce both alcohol and calorie consumption. 4. Activity – Increase daily movement, for example, an extra 10 min of walking (~1000 steps) as a starting point, building toward more moderate activity over time, as well as simple home-based muscle strengthening activities on two days per week, if possible. 5. Treatment – Recommend antihypertensive medication in those at elevated cardiovascular risk or when SBP is above a certain level. For those at lower cardiovascular risk, one could wait to see if lifestyle changes prove sufficient. If, after 3–6 months, blood pressure remains elevated, then pharmacological treatment would be necessary. This mnemonic is inspired by successful public health tools such as the FAST mnemonic for stroke recognition, which has been widely adopted and proven effective in promoting rapid response. Similarly, SWAAT offers a practical, easy-to-remember framework that empowers individuals to take proactive steps toward improving blood pressure and overall health. A simple tool like SWAAT can help promote healthier lifestyles, reduce cardiovascular risk, and encourage long-term health improvements. Data from the Framingham Heart Study showed that the excess risk of cardiovascular disease attributed to obesity was 54% in women versus 46% in men [9,10]. Early identification and management of elevated blood pressure – even in the pre-diabetes range – can prevent progression to more serious conditions such as heart disease, stroke, and diabetes [11]. Furthermore, an initiative-taking approach to health could lead to broader societal benefits, including improved productivity, fewer sick days, and a more engaged workforce. We believe SWAAT represents a modest but important extension of prior public health strategies and could serve as a valuable resource for both clinicians and patients. We encourage discussion and adoption of this mnemonic as part of routine hypertension management. ACKNOWLEDGEMENTS Funding: None. Conflicts of interest N.S. has consulted for and/or received speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gan & Lee, GlaxoSmithKline, Hanmi Pharmaceuticals, Kailera, Mass Medicines, Menarini-Ricerche, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, UCB Pharma, and Verdiva Bio; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche outside the submitted work. For the remaining authors none were declared.